158
Participants
Start Date
August 31, 2006
Primary Completion Date
May 31, 2007
Study Completion Date
May 31, 2007
Keppra® extended release formulation - XR
500mg extended release oral tablet, 2 tablets once daily
Placebo
oral tablets, 2 tablets once daily
N01235 1007, Curitiba
N01235 2001, Kuopio
N01235 2003, Tampere
N01235 2002, Turku
N01235 3008, Chennai
N01235 3010, Chennai
N01235 3012, Gandhinagar
N01235 3003, Hyderabad
N01235 3004, Hyderabad
N01235 3001, Lucknow
N01235 3009, Madurai
N01235 3002, Mumbai
N01235 3007, Mumbai
N01235 3011, Visakhapatnam
N01235 4006, Aguascalientes
N01235 4003, Distrio Federal
N01235 4001, Guadalajara
N01235 4005, Puebla City
N01235 5001, Moscow
N01235 5002, Moscow
N01235 5003, Moscow
N01235 5005, Moscow
N01235 5006, Moscow
N01235 5007, Moscow
N01235 5004, Saint Petersburg
N01235 5009, Saint Petersburg
N01235 5008, Smolensk
N01235 6002, Cape Town
N01235 6003, Umhlanga
N01235 7001, Kharkiv
N01235 7004, Kharkiv
N01235 7005, Lviv
N01235 7002, Odesa
N01235 7003, Poltava
Lead Sponsor
UCB Pharma
INDUSTRY